Please assess the completion status of the following clinical trial:

Trial Title: Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, term pregnant female with a gestational age of 37-42 weeks (singleton)~* Undergoing a planned primary and uncomplicated caesarean section (CS) for their first born under regional anaesthesia~* Aged between 18 and 40 years (both inclusive)~* Ability to communicate well with the Investigator and to comply with the requirements of the entire study~* Willing to give informed consent in writing.~Exclusion Criteria:~* Being obese with BMI ≥35 before pregnancy~* History of, or existing thromboembolic, cardiovascular or cerebrovascular disorder~* History of cervical cancer~* History of severe infection of the uterus~* Previous surgery of the cervix or uterus or any other (previous) condition that could interfere with the measurement of uterine contractility~* Any clinically significant abnormality following review of medical history, laboratory result and physical examination at screening as judged by the Investigator~* Conditions or disorders that might affect the absorption, distribution, metabolism or excretion of any of the study medication~* Contraindications for oxytocin use~* Hypersensitivity to the active substances or to any of the excipients of the investigational product (test product or comparator drug)~* Present use or use within 30 days before the start of the study medication of one or more of the following medications: antihypertensive drugs, anti-coagulant therapy, medication that could affect myometrial contractility, sex steroids, prostaglandins and its analogues, inhalation anaesthetics, vasoconstrictors/sympathomimetics and caudal anaesthetics, vasopressin-like drugs~* Administration of any other investigational drug within 3 months before first dosing~* Tobacco use (smoking or snuffing), currently or within the last 6 months before screening

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Oxytocin intravenous (Type: EXPERIMENTAL): single dose of intravenous (IV) oxytocin
- Oxytocin tablet (Type: EXPERIMENTAL): single dose of oxytocin tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).